US biotech Mammoth Biosciences, which is building the next generation of CRISPR products to cure and detect disease, has reinforced its C-suite with the arrival of two industry veterans - Phil Tinmouth as chief business officer, and Siang Chin as general counsel.
The pair’s strategic executive leadership should propel Mammoth’s efforts to reshape therapeutics and diagnostics with its expansive pipeline of CRISPR-based products, including “ultra-compact” CRISPR system to support the development of one-time, in vivo cures.
Mr Tinmouth’s experience includes a 20+ year career at Vertex Pharmaceuticals, earning his role as vice president/head of business development and helping grow what was an $800 million company at the beginning of his tenure into the $50 billion pharma giant it is today. He joins Mammoth from Pardes Biosciences, where he led business development and strategic initiatives as Chief Business and Strategy Officer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze